Related Experiment Video

Updated: Apr 12, 2026

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice
09:29

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice

Published on: July 14, 2023

1.4K

Prognostic value of galectin-3 in patients with heart failure

Ivica Bošnjak1, Kristina Selthofer-Relatić2, Aleksandar Včev3

  • 1Department for Cardiovascular Disease, Clinic for Internal Medicine, University Hospital Centre Osijek, J. Huttlera 4, 31000 Osijek, Croatia.

Disease Markers
|May 12, 2015
PubMed

Insights

Galectin-3, a key protein in heart failure, is linked to patient outcomes and disease progression. Research highlights its role in myocardial remodeling and potential for new heart failure treatments.

Area of Science:

  • Biochemistry
  • Cardiology
  • Immunology

Background:

  • Galectins are soluble lectins involved in inflammation, immunity, and cancer.
  • Galectin-3 plays a significant role in the development and progression of heart failure.
  • Elevated plasma levels of galectin-3 correlate with adverse heart failure outcomes, including rehospitalization and mortality.

Purpose of the Study:

  • To summarize recent advancements in galectin-3 research.
  • To elucidate the role of galectin-3 in the pathophysiology of myocardial remodeling and heart failure.
  • To explore the implications of galectin-3 in developing novel heart failure therapeutics.

Main Methods:

  • Literature review of recent studies on galectin-3 and heart failure.
  • Analysis of the role of galectin-3 in myocardial remodeling.
  • Investigation of galectin-3's involvement in heart failure with preserved and reduced ejection fraction.

Main Results:

  • Galectin-3 is implicated in the complex mechanisms underlying heart failure development.
  • Plasma galectin-3 levels serve as a prognostic biomarker for heart failure.
  • Understanding galectin-3's role provides insights into potential therapeutic targets.

Conclusions:

  • Galectin-3 is a critical mediator in heart failure pathophysiology.
  • Targeting galectin-3 may offer a promising strategy for novel heart failure therapies.
  • Further research into galectin-3's functions can advance treatment for heart failure patients.

More Related Videos

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.4K

Related Concept Videos

Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
916
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
618
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
767
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.5K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
465